TOP ONCOLOGY CRO
EXPERTS IN CLINICAL ONCOLOGY
QUALITY ONCOLOGY TRIAL MONITORING
home blog news careers français contact
QUALITY ONCOLOGY TRIAL MANAGEMENT



The Reverse Feasibility Program™

A Novel CRO Approach to Site Selection
& Patient Recruitment

Reverse Feasibility Program for 50% faster site start-up.A revolutionary approach to feasibility assessment that accelerates study start-up by matching your protocol with the current study needs of motivated and pre-qualified North American sites.

How it works...


Oncology Clinical Trial News

Scimega launches Canadian expansion efforts for an ongoing randomized Phase III trial of Autologous Dendritic Cell Immunotherapy in patients with Advanced Renal Cell Carcinoma.

Scimega launches Phase IV study to evaluate the resistance mechanisms and real-world pharmacoeconomics of an ALK/ROS1 inhibitor and its companion diagnostic test in patients with advanced ALK-positive non-small cell lung cancer (NSCLC).

Scimega launches Canadian expansion efforts for an ongoing Phase 3 Study of a third-generation Tyrosine Kinase Inhibitor (TKI) in patients with Chronic Phase - Chronic myelogenous (or myeloid) leukemia.

Scimega launches Phase II study to identify predictive biomarkers for 2nd-line treatment with an oral multi-kinase inhibitor in patients with metastatic Colorectal Cancer.

Upcoming Scimega Events

Clinical Operations in Oncology Trials – West Coast

April 16 - 17, 2014 in San Francisco

ASCO 2014

May 30 – June 3, 2014 in Chicago, IL

Clinical Operations in Oncology Trials –
East Coast

July 15-16, 2014 in Boston

See all upcoming events...


Latest Podcast

Reverse Feasibility in Action

An Interview with Dr. Quincy Chu
Listen...



Copyright © Scimega Research Inc. 2013. All rights reserved.
Privacy Policy

Clinical CRO   Clinical Trial Monitoring   Clinical Trial Management   Oncology Community